Assessment of screening practices in a subacute clinical setting following introduction of Trichomonas vaginalis nucleic acid amplification testing

Wisconsin Medical Journal

Volumn 111, Issue 5, 2012, Pages 233-236

  Munson, Erik ^a,b   Miller, Cheryl ^a   Napierala, Maureen ^a   Kramme, Timothy ^a   Olson, Robin ^a   Munson, Kimber L ^a   Olson, Sarah ^a   Hryciuk, Jeanne E ^a   Schell, Ronald F ^c,d  

^a Wheaton Franciscan Healthcare St Francis   (United States)

^b UNIVERSITY OF WISCONSIN MILWAUKEE   (United States)

^c WISCONSIN STATE LABORATORY OF HYGIENE   (United States)

^d UNIVERSITY OF WISCONSIN MADISON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

RNA;

ARTICLE; CHLAMYDIA TRACHOMATIS; CLINICAL ASSESSMENT; CLINICAL PRACTICE; DIAGNOSTIC TEST; GENETIC SCREENING; HUMAN; MICROORGANISM DETECTION; MICROSCOPY; NEISSERIA GONORRHOEAE; NONHUMAN; NUCLEIC ACID AMPLIFICATION; SCREENING TEST; SEXUALLY TRANSMITTED DISEASE; TRICHOMONAS VAGINALIS;

CHLAMYDIA INFECTIONS; FEMALE; GONORRHEA; HUMANS; MASS SCREENING; NUCLEIC ACID AMPLIFICATION TECHNIQUES; SENSITIVITY AND SPECIFICITY; SEXUALLY TRANSMITTED DISEASES, BACTERIAL; TRICHOMONAS VAGINITIS;

EID: 84868352839     PISSN: 10981861     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Weinstock H, Berman S, Cates W Jr. Sexually transmitted diseases among American youth: incidence and prevalence estimates. Perspect Sex Reprod Health. 2004;36(1):6-10.
2. Chesson HW, Blandford JM, Pinkerton SD. Estimates of the annual number and cost of new HIV infections among women attributable to trichomoniasis in the United States. Sex Transm Dis. 2004;31(9):547-551.
3. Guenthner PC, Secor WE, Dezzutti CS. Trichomonas vaginalis-induced epithelial monolayer disruption and human immunodeficiency virus type 1 (HIV-1) replication: implications for the sexual transmission of HIV-1. Infect Immun. 2005;73(7):4155-4160.
4. Kissinger P, Amedee A, Clark RA, et al. Trichomonas vaginalis treatment reduces vaginal HIV-1 shedding. Sex Transm Dis. 2009;36(1):11-16.
5. Heine P, McGregor JA. Trichomonas vaginalis: a reemerging pathogen. Clin Obstet Gynecol. 1993;36(1):137-144.
6. Huppert JS, Mortensen JE, Reed JL, et al. Rapid antigen testing compares favorably with transcription-mediated amplification assay for the detection of Trichomosas vaginalis in young women. Clin Infect Dis. 2007;45(2):194-198.
7. Munson E, Napierala M, Olson R, et al. Impact of Trichomonas vaginalis transcription-mediated amplification-based analyte-specific-reagent testing in a metropolitan setting of high sexually transmitted disease prevalence. J Clin Microbiol. 2008;46(10):3368-3374.
8. Centers for Disease Control and Prevention. 2010 Sexually Transmitted Disease Surveillance. Atlanta, GA: U.S. Department of Health and Human Services; 2011.
9. Chernesky M, Jang D, Luinstra K, et al. High analytic sensitivity and low rates of inhibition may contribute to detection of Chlamydia trachomatis in significantly more women by the APTIMA Combo 2 assay. J Clin Microbiol. 2006;44(2):400-405.
10. Huppert JS, Hesse E, Kim G, et al. Adolescent women can perform a point-of-care test for trichomoniasis as accurately as clinicians. Sex Transm Infect. 2010;86(7):514-519.
11. Munson E, Napierala M, Basile J, et al. Trichomonas vaginalis transcriptionmediated amplification-based analyte-specific reagent and alternative target testing of primary clinical vaginal saline suspensions. Diagn Microbiol Infect Dis. 2010;68(1):66-72.
12. Nye MB, Schwebke JR, Body BA. Comparison of APTIMA Trichomonas vaginalis transcription-mediated amplification to wet mount microscopy, culture, and polymerase chain reaction for diagnosis of trichomoniasis in men and women. Am J Obstet Gynecol. 2009;200(2):188. e1-7.
13. Napierala M, Munson E, Munson KL, et al. Three-year history of transcriptionmediated amplification-based Trichomonas vaginalis analyte-specific reagent testing in a subacute care patient population. J Clin Microbiol. 2011;49(12):4190-4194.
14. Bruckner DA. Urogenital specimens, direct saline mount. In: Isenberg HD, ed. Clinical Microbiology Procedures Handbook, 2nd ed. Washington DC: ASM Press; 2004: 9.6.6.1-9.6.6.4.
15. Gaydos CA, Quinn TC, Willis D, et al. Performance of the APTIMA Combo 2 assay for detection of Chlamydia trachomatis and Neisseria gonorrhoeae in female urine and endocervical swab specimens. J Clin Microbiol. 2003;41(1):304-309.
16. Kramme T, Munson K, Miller C, Napierala M, Olson R, Munson E. Live Trichomonas vaginalis ASR testing in a high-prevalence STI metropolitan area: female epidemiology, abstract 2120. 111th General Meeting of the American Society for Microbiology. New Orleans, LA; 2011.
17. Munson E, Firmani M. Molecular diagnosis of Neisseria gonorrhoeae infection in the United States. Expert Opin Med Diagn. 2009;3(3):327-343.
18. Schwebke JR, Hobbs MM, Taylor SN, et al. Molecular testing for Trichomonas vaginalis in women; results from a prospective US clinical trial. J Clin Microbiol. 2011;49(12):4106-4111.
19. Ferris DG, Hamrick HJ, Pollock PG, et al. Physician office laboratory education and training in primary care residency programs. Arch Fam Med. 1995;4(1):34-39.
20. Steindel SJ, Granade S, Lee J, et al. Practice patterns of testing waived under the clinical laboratory improvement amendments. Arch Pathol Lab Med. 2002;126(12):1471-1479.
21. Stull TM, Hearn TL, Hancock JS, Handsfield JH, Collins C. Variation in proficiency testing performance by testing site. JAMA. 1998;279(6):463-467.
22. Garber GE. The laboratory diagnosis of Trichomonas vaginalis. Can J Infect Dis Med Microbiol. 2005;16(1):35-38.
23. Rein MF, Chapel TA. Trichomoniasis, candidiasis, and the minor venereal diseases. Clin Obstet Gynecol. 1975;18(1):73-88.